Search 

Domainex is an integrated drug discovery services company, which uses its medicinal chemistry expertise, its in silico hit screening approach and proprietary discovery technology platform, CDH, to improve efficiency in developing drug candidates.

- LeadBuilder, is a state-of-the-art virtual screening capability that identifies compounds with "lead-like" properties, ideal for progressing to drug candidates and saving 6-12 months on standard approaches.
- Combinatorial Domain Hunting (CDH), enables the fast identification of expressible (in E.coli or baculovirus) domains of drug target protein, which are able to bind ligand.

The identified protein domains are then used to quickly develop binding/activity assays for use in small molecule hit screening. This entire process only takes 4-5 months for novel drug targets and so can quickly de-rate limit exciting and challenging discovery programs. The Domainex services enhance drug discovery projects from target expression to small molecule lead optimization. Its success is illustrated by the number of drug candidates it has developed with 6 projects reaching Candidate Drug in the last 4 years (3 currently in the clinic). This success has been due to Domainex's focus on high quality, intelligence-driven drug design, supported by the expertise of its scientists.